Q-omics provides the consensus-scored MIR613 profile across patient tissues and cancer cell-line models. MIR613 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MIR613 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MIR613 RNA expression shows 8,940 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, BRCA, and TGCT as cancer lineages where MIR613 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR613 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR613 survival associations across molecular data types. MIR613 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR613 RNA expression–survival associations across cancer types. High MIR613 expression shows unfavorable associations in THYM, UVM, ACC, KICH, MESO and BLCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MIR613 RNA expression.
This table summarizes MIR613 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR613. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR613 shows higher tumor expression in BRCA, COAD and KIRC. The BRCA box plot shows higher MIR613 RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p < 0.001).
This table shows molecular features associated with MIR613 in patient tissues and cancer cell lines. In patient samples, MIR613 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
